I think where I got hung up on the 25% and 30% RRR numbers was back when the company slides detailed SERMO data:

https://www.resverlogix.com/upload/event/18/c38685f1ce18/biopharm-america-2017.pdf

On page 11 of that slide deck, image #22 it shows the....I'll just cut and paste:

Based on responses from 1,920 primary care physicians (n=625), cardiologists (n=550), endocrinologists (n=420) and nephrologists (n=325) 

If select BET inhibition in a large phase III prospective setting illustrates significant relative risk reduction of MACE, on top of standard of care, in diabetes patients with low HDL and an ACS comorbidity, what would your level of interest be in prescribing this drug for the following risk reductions? 

There follows a bar graphic that shows 87% of those surveyed showing interest in perscribing if Apabetalone proved 25% RRR and 90% if RRR was 30% or higher.